Which statement about immunosuppressive therapy is true for balancing risk?

Which statement about immunosuppressive therapy is true for balancing risk?

• A. Higher immunosuppression reduces infection risk.
• B. Adequate immunosuppression lowers rejection risk but increases infection risk; drug levels must be monitored.
• C. Immunosuppressants do not affect infection risk.
• D. You should always stop immunosuppressants if infection occurs.

Answer: (B)

The key idea here is balancing the risk of rejection with the risk of infection when using immunosuppressive therapy. These drugs work by dampening the immune system, which helps prevent the body from attacking a transplanted organ or from overreacting in autoimmune disease, but this same dampening lowers the body’s ability to fight infections. Because each patient metabolizes these medications differently and many drugs have narrow, specific target levels, clinicians actively monitor drug levels and adjust dosing to keep them within a safe, effective range. If the levels are too low, rejection becomes more likely; if they’re too high, infection risk and drug toxicity rise. That’s why adequate immunosuppression paired with careful monitoring of drug levels is the best approach to balance these competing risks. Infection risk clearly increases with greater immunosuppression, so saying that higher immunosuppression reduces infection risk is inconsistent with how these drugs work. Immunosuppressants do affect infection risk, which is why monitoring and prophylactic measures are important. And stopping immunosuppressants outright during infection is not the standard rule; management usually involves adjusting dosing and providing appropriate infection treatment while maintaining some level of immunosuppression to prevent rejection.

The key idea here is balancing the risk of rejection with the risk of infection when using immunosuppressive therapy. These drugs work by dampening the immune system, which helps prevent the body from attacking a transplanted organ or from overreacting in autoimmune disease, but this same dampening lowers the body’s ability to fight infections. Because each patient metabolizes these medications differently and many drugs have narrow, specific target levels, clinicians actively monitor drug levels and adjust dosing to keep them within a safe, effective range. If the levels are too low, rejection becomes more likely; if they’re too high, infection risk and drug toxicity rise. That’s why adequate immunosuppression paired with careful monitoring of drug levels is the best approach to balance these competing risks.

Infection risk clearly increases with greater immunosuppression, so saying that higher immunosuppression reduces infection risk is inconsistent with how these drugs work. Immunosuppressants do affect infection risk, which is why monitoring and prophylactic measures are important. And stopping immunosuppressants outright during infection is not the standard rule; management usually involves adjusting dosing and providing appropriate infection treatment while maintaining some level of immunosuppression to prevent rejection.